Form 4: Moderna CFO Reports Stock Transactions

Moderna's Chief Financial Officer, James M. Mock, has reported transactions involving the acquisition and disposition of company stock, including the settlement of restricted stock units and tax withholding.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc., reported transactions on June 1, 2026.
• He acquired 2,475 shares of common stock through the conversion of restricted stock units (RSUs).
• Following this, 1,197 shares were disposed of to cover tax withholding obligations related to the vesting of RSUs, at a price of $47.19 per share.
• After these transactions, Mock beneficially owns 59,594 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine insider transactions related to equity compensation and tax obligations, with no indication of significant positive or negative strategic shifts.

Positives

• The CFO's acquisition of shares through RSU conversion indicates continued equity participation and alignment with the company's performance.
• The vesting of RSUs suggests that performance or time-based conditions have been met.

Negatives

• A portion of the vested shares were sold to cover tax obligations, which is a common but represents a reduction in direct shareholding.
• The disposal of 1,197 shares for tax withholding at a price of $47.19 per share, if this price is below current market value, could be seen negatively, though the filing does not provide market context for this specific transaction.

Risks

• The filing does not explicitly mention any new risks or challenges.
• However, the disposal of shares for tax withholding is a standard event that can reduce an executive's direct ownership, which could be perceived as a minor negative by some investors if not balanced by other factors.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders and reflect standard equity compensation practices. The transactions reported by Moderna's CFO are typical for executives managing RSU vesting and associated tax liabilities.

Comparison to Industry Standards

• The vesting schedule for RSUs, with 25% vesting initially and the remainder in quarterly installments, is a common practice across the biotechnology and pharmaceutical industries.
• The practice of withholding shares to cover tax liabilities upon vesting is a standard and widely accepted method used by public companies to manage executive compensation costs and compliance.

Stakeholder Impact

• Shareholders: The transactions do not directly indicate a change in the CFO's long-term conviction in the company, as the share disposition was for tax purposes. The net change in beneficial ownership is relatively small in the context of total outstanding shares.
• Employees: The RSU vesting and settlement process is a standard component of executive compensation, aligning management interests with those of shareholders.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued vesting of the remaining restricted stock units in quarterly installments as per the award agreement.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Chief Financial Officer, James M. Mock